Mizuho America, Inc.

Mizuho America, Inc., a foreign-owned Tokyo-based supplier with U.S. operations in Union City, California, supplies high-precision surgical instruments, implants, and operating room equipment to federal healthcare facilities as a prime contractor under full-and-open competition with no set-aside designation. The company operates exclusively as a prime (100% of recent awards); it does not subcontract and does not participate in set-aside categories.

Mizuho's federal capability portfolio centers on specialized neurosurgical, vascular, and orthopedic instruments and surgical tables. Representative recent work includes a $141,752 firm-fixed-price purchase order from Department of Veterans Affairs Veterans Integrated Service Network 16 for T2 surgical implants (August 2025), a $94,904 order from VISN 7 for a Mizuho surgical table full service base and four additional units (October 2024, running through September 2029), a $141,422 sole-source award from the Defense Health Agency for an E3 Series Evans Elite Endoscopic Instrument Set to support Naval Medical Center San Diego (November 2022), and a September 2026 $81,234 purchase order from VISN 22 for Kelly Endonasal Instrument Sets. The company's work is dominated by procurement of named Mizuho-brand products (surgical tables, headframes, instrument sets) and other precision surgical devices classified under NAICS 339112 (Surgical and Medical Instrument Manufacturing) and PSC 6515 (Medical and Surgical Instruments, Equipment, and Supplies).

Mizuho's customer base is heavily concentrated in federal healthcare: the top five funding agencies account for 64% of combined potential value. The Department of the Navy Bureau of Medicine and Surgery leads with 41 awards valued at $553 thousand combined potential value, followed by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 (11 awards, $493 thousand), the Defense Health Agency (9 awards, $355 thousand), VISN 7 (4 awards, $259 thousand), and the Army Medical Command (7 awards, $167 thousand). The dollar concentration aligns with volume concentration — no tension exists between the two rankings.

Award activity has been sparse and flat over the past five years: one award in 2022, one in 2023, two in 2024, one in 2025, and two in 2026 year-to-date. The combined portfolio carries only $2.8 million in combined potential value across 156 awards since 1997, indicating a small-dollar transaction volume characteristic of medical equipment procurement. Two awards face ultimate completion within the next twenty-four months (combined potential value $142 thousand), creating minimal recompete exposure. Mizuho competes full-and-open with no set-aside certifications and carries no parent vehicles or consortia memberships in the federal marketplace.